AI Insight
Two Phase III clinical trials led by Northwestern University tested retatrutide, an experimental injectable weight-loss drug, in over 1,000 participants with knee osteoarthritis who were overweight or obese. Participants taking the highest dose lost approximately 25% of their body weight on average. The drug appears to ease painful symptoms of knee osteoarthritis while producing significant weight reduction.
Why it matters
For the millions of people suffering from knee osteoarthritis who are overweight or obese, this drug could potentially address both excess weight and joint pain simultaneously, improving mobility and quality of life for everyday activities like walking and climbing stairs. The dual benefit could represent a new treatment approach for this common and debilitating condition.
Understand the Science
For people with painful knee osteoarthritis (OA) who are overweight or have obesity, everyday activities such as walking, climbing stairs and standing up from a chair can be difficult. In two Northwestern University–led Phase III clinical trials involving more than 1,000 participants combined, those taking the highest dose of retatrutide, a new experimental weight-loss injectable drug, lost about one-quarter of their body weight on average.
Source: Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials